Abstract:Objective: To explore the value of combined measurement of nuchal translucency (NT), cervical length (LC), free beta-human chorionic gonadotropin (B-HCG), pregnancy-associated plasma protein-A (PAPPA), and D-dimer (D-D) in assessing pregnancy outcomes in high-risk pregnant women. Methods: A retrospective study included 80 high-risk pregnant women who visited our hospital from January 2019 to January 2022. Participants were categorized into groups with adverse pregnancy outcomes and those without. The differences in NT, LC, arterial S/D ratio, PI, RI, serum B-HCG, PAPPA, and D-D levels were compared between the two groups. The correlation between these indicators and their predictive value for adverse pregnancy outcomes were analyzed. Results: Pregnant women with adverse pregnancy outcomes had significantly higher levels of B-HCG, PAPPA, D-D, and NT (2.28±0.62 mom, 0.72±0.16 mom, 351.12±82.80 mg/L, and 3.78±0.81 mm, respectively) compared to those without adverse outcomes (1.75±0.41 mom, 0.57±0.15 mom, 295.33±85.52 mg/L, and 3.31±0.64 mm, respectively) (P<0.01). LC was significantly lower in women with adverse outcomes (24.49±4.53 mm) compared to those without adverse outcomes (31.01±5.12 mm) (P<0.01). B-HCG, PAPPA, and D-D levels were positively correlated with NT (P<0.05), while negatively correlated with LC (P<0.05). The combined use of NT, LC, B-HCG, PAPPA, and D-D in predicting adverse pregnancy outcomes in high-risk pregnant women had an AUC of 0.911 (95% CI: 0.848–0.974), significantly higher than individual indicators. The sensitivity and specificity were 79.20% and 96.30%, respectively (P<0.01). Conclusion: NT, LC, B-HCG, PAPPA, and D-D are correlated with adverse pregnancy outcomes in high-risk pregnant women, and their combined use has good predictive value for adverse pregnancy outcomes in high-risk pregnancies.